Skip to main content

Table 2 Investigations performed by respondents (in %) with recommendations of the Dutch and ESHRE guideline

From: Identifying discrepancies between clinical practice and evidence-based guideline in recurrent pregnancy loss care, a tool for clinical guideline implementation

Investigations

Number of respondents

Respondents (%)

Dutch guideline

ESHRE guideline

General Aspects

BMI

Lifestyle

Blood pressure

348/373

343/373

93/373

93

92

25

Recommended

Yes

Yes

*

Recommended

Yes

Yes

*

Genetic factors

Female karyotype

Male karyotype

Pregnancy tissue array

262/363

260/363

8/363

72

72

2

On indication

On indication

Not recommended

On indication

On indication

Explanatory purpose only

Antiphospholipid syndrome

ACA IgG

ACA IgM

Lupus Anticoagulant

Anti-β2-glycoprotein IgG

Anti-β2-glycoprotein IgM

318/350

294/350

321/350

148/350

129/350

91

84

92

42

37

Recommended

Yes

Yes

Yes

*

*

Recommended

Yes

Yes

Yes

Yes

Yes

Endocrine factors

TSH

TPO antibodies

T4 and/or T3

Progesterone

LH/FSH

Glucose

HbA1c

195/345

92/345

82/345

6/345

7/345

51/345

29/345

57

27

24

2

2

15

8

Not recommended

*

Not recommended

Not recommended

Not recommended

Not recommended

Not recommended

Recommended

Recommended

Not routinely recommended

Not recommended

Not recommended

Not recommended

Not recommended

Uterine factors

2D ultrasound

3D ultrasound

HSG

Hysteroscopy

SIS

MRI

266/347

31/347

11/347

55/347

71/347

4/347

77

9

3

16

21

1

*

Recommended

Preferred technique

Male investigations

Sperm DNA fragmentation

Semen analysis

Lifestyle

10/331

4/331

199/331

3

1

60

*

Explanatory purpose

*

*

Ongoing pregnancy

hCG

Progesterone

Pregnancy tissue karyotype

Pregnancy tissue array

Ultrasound

HbA1c

Glucose

7/333

5/333

7/333

5/333

270/333

2/333

5/333

2

2

2

2

81

1

2

*

*

Not recommended

*

Yes

*

*

*

Thrombophilia

Antithrombin – III

APC-resistance

APTT

Factor II mutation

Factor V Leiden

Factor VIII

Factor X

Protein C

Protein S

Fibrinogen

INR

Thrombin time

Homocysteine

Plasminogen

105/358

83/358

37/358

80/358

105/358

41/358

16/358

120/358

127/358

18/358

9/358

20/358

206/358

4/358

29

23

10

22

29

12

5

34

36

5

3

6

58

1

On indication

Yes

Yes

*

Yes

Yes

Yes

*

Yes

Yes

*

*

*

Yes

*

Not routinely recommended

Infections

CMV

Chlamydia

Gonorrhea

9/342

17/342

12/342

3

5

4

*

Not recommended

Immunological factors

NK-cell plasma level

NK-cell level in endometrial biopsy

HLA typing and sharing

HLA antibodies

ANA antibodies

2/342

1/342

2/342

2/342

13/342

1

0

1

1

4

*

Not recommended

Not recommended

Not recommended

Not recommended

Explanatory purpose

  1. * Not indicated
  2. Number indicated regards percentage of respondents that perform karyotyping according to individual risk assessment table
  3. BMI: Body Mass Index; ACA: Anticardiolipin Antibodies; TSH: Thyroid Stimulating Hormone; TPO: Thyroid Peroxidase; HSG: Hysterosalpingography; SIS: Saline Infusion Sonohysterography; HbA1c: glycated hemoglobin; CMV: Cytomegalovirus; NK: Natural Killer; HLA: Human Leukocyte Antibiodies; ANA: Antinuclear Antibodies